ReiThera

ReiThera is a dual-focus Italian biotech, functioning both as a specialized CDMO for viral vectors and as a developer of its own therapeutic candidates. Its core expertise lies in viral vector engineering and scalable GMP manufacturing for adenoviruses, AAV, Lentivirus, MVA, and Herpes Simplex vectors. The company is advancing a clinical-stage HIV vaccine candidate in partnership with major research institutes and is actively involved in outbreak response efforts, such as for Marburg virus, while serving a global client base from its state-of-the-art facility in Rome.

Viral vector engineering and GMP manufacturing platform for Adeno-Associated Virus (AAV), Lentivirus, Adenovirus (AdV), Modified Vaccinia Ankara (MVA), and Herpes Simplex Vector.

As a CDMO, ReiThera competes with large multinationals like Lonza, Catalent, and Charles River, as well as other specialized viral vector CDMOs. In vaccine development, it competes with large pharma and numerous biotechs in the HIV and emerging pathogen spaces. Its differentiation lies in its integrated platform, specific viral vector expertise, and agile, partnership-focused approach.